The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Outcomes of BCMA-exposed vs BCMA-naïve patients with R/R multiple myeloma
Al-Ola Abdallah, MD, University of Kansas Medical Center, Westwood, KS, comments on a retrospective study comparing the outcomes of patients with penta-relapsed refractory multiple myeloma treated with BCMA-directed therapy vs other anti-myeloma therapies. The study identified a benefit in overall survival (OS) for those treated with BCMA-directed therapy over those who were not; however, how to sequence BCMA-directed therapy for these patients requires further investigation. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
